Navigation Links
LX4211 for Diabetes Shown to Reduce Fasting and Post-Prandial Blood Sugar in Healthy Subjects
Date:9/13/2011

le metabolic effects in healthy subjects, together with the safety profile observed to date, suggest that LX4211 could be considered earlier in the diabetes treatment paradigm, perhaps including the potential treatment of pre-diabetes in patients with impaired glucose tolerance or impaired fasting glucose (IGT/IFG)."

About the Clinical Trial

The clinical trial was designed to assess the effect of different LX4211 dose schedules relative to meal time  in healthy subjects when taken as a single daily dose (400 mg) or a split dose (200 mg twice daily).  Subjects were randomized to LX4211 in an ordered sequence to assess the pharmacodynamic effects of different dosing times, ranging from 1 hour prior to meals to immediately prior to meals.  Pharmacodynamic effects, include urinary glucose excretion, fasting plasma glucose, insulin, PYY and GLP-1 (total and active) were assessed at multiple time points during the 12-day dosing period.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of LX4211, including characterizations of the results of and projected timing o
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
2. Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
3. Lexicon Presents Data Describing LX4211 Positive Phase 2 Clinical Results and Novel Mechanism of Action for Type 2 Diabetes
4. Lexicon Announces Positive Results from New Clinical Study of LX4211 in Type 2 Diabetes Patients
5. Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
6. Lexicon Presents LX4211 Clinical Data at European Association for the Study of Diabetes Annual Meeting
7. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
8. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
9. The Heart, Diabetes, And Weight Loss Centers of New York Introduce the New Science of Metabolic Diagnosis and Weight Management
10. Isis Initiates Phase 1 Study of ISIS 325568 Targeting Glucagon Receptor to Treat Type 2 Diabetes
11. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... , March 31, 2015 Accelerated ... the American Association of Orthodontics 2015 Annual Session, ... orthodontists present scientific lectures on AcceleDent ® . ... leader in accelerated orthodontics, AcceleDent is a FDA-cleared, ... treatment by as much as 50 percent with ...
(Date:3/31/2015)... DALLAS , March 31, 2015 ... H1 2015" therapeutic market research report of 68 ... its online business intelligence library. The ... information on the therapeutic development for Pemphigus ... therapeutics assessment by drug target, mechanism of action ...
(Date:3/31/2015)... Ryan & Maniskas, LLP is ... Hyperion Therapeutics, Inc. ("Hyperion" or the "Company") (NASDAQ: ... other violations of law related to the Company,s efforts ... a transaction valued at approximately $1.1 billion. ... to learn more about this class action or if ...
Breaking Medicine Technology:Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 2Leading Orthodontists to Advance Accelerated Treatment at AAO 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 2Pemphigus Therapeutic Development and Pipeline Review H1 2015 3Pemphigus Therapeutic Development and Pipeline Review H1 2015 4Ryan & Maniskas, LLP Announces Investigation of Hyperion Therapeutics, Inc. 2
... 25, 2011 Renowned biochemist Michael A. Marletta, ... as the next president of The Scripps Research Institute, effective ... MD, who has led the institution for 25 years. ... Marletta, past Chair of the Department of ...
... 2011 ERT (Nasdaq: ERES ), announced ... CEO, and Keith Schneck, the Company,s Chief Financial Officer, ... Health Care Conference at 10:00 AM ET on March 2, ... may access the presentation by visiting the Company,s corporate ...
Cached Medicine Technology:The Scripps Research Institute Names Michael A. Marletta as President 2The Scripps Research Institute Names Michael A. Marletta as President 3The Scripps Research Institute Names Michael A. Marletta as President 4ERT to Present at the Citi 2011 Global Health Care Conference on March 2, 2011 2
(Date:3/31/2015)... (PRWEB) March 31, 2015 Medical DNA ... has met all criteria for Laboratory Accreditation by COLA, ... only to laboratories that apply rigid standards of quality ... of proficiency testing, and pass a rigorous on-site laboratory ... accreditation as a result of a long-term commitment to ...
(Date:3/31/2015)... 31, 2015 Students, teachers, and the ... education in a drastically different way as current and ... and training content is being delivered and received. , ... technology in an unprecedented way with education becoming individualized, ... co-founder and CEO, My Mobile University , This ...
(Date:3/31/2015)... Clinovo, a leading provider of ... , the premiere voice of Northern California’s Life ... companies. , BayBio brings together the collective ... and productive life science cluster, helping companies grow, ... most pressing challenges. , “We are thrilled ...
(Date:3/31/2015)... 31, 2015 Dr. Russell Ashinoff is a ... He was recently quoted in an Asbury Park Press ... issues, causing fluid retention and tissue swelling. Dr. Ashinoff ... and / or improve lymphedema symptoms. , “The ... the symptoms of lymphedema. The goal is to improve ...
(Date:3/31/2015)... (PRWEB) March 31, 2015 Dr. Uzma Parvez ... March 19th, Dr. Parvez conducted Grand Grounds Presentations at St. ... Opioids and Managing Side Effects”. The event was attended ... She received very positive feedback from the Grand Rounds. ... best that they’ve had in a while. , Ahead, ...
Breaking Medicine News(10 mins):Health News:Local Medical DNA Labs, LLC. Recognized for Quality Laboratory Services 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 2Health News:LTT Global Communications Launches First Asia Holistic Online Learning Platform 3Health News:Clinovo Joins BayBio Membership Program, The Leading Life Science Association in Northern California 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 2Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 3Health News:The Physicians at Plastic Surgery Center Each Have Something to Celebrate This March 4Health News:NJ Top Docs Presents, Dr. Uzma Parvez of Total Pain Care 2
... organizations have called on the medical profession to ... health between Indigenous and non-Indigenous Australians . ... of Australia, Dr Mark Wenitong, President of the ... the National Aboriginal Community Controlled Health Organization and ...
... Indigenous mothers living in remote areas are 14 per cent ... in regional or city areas say Indigenous health researchers ... Womens and Childrens Health at the University of New South ... Welfare National Perinatal Statistics Unit and her colleagues, examined whether ...
... the brain to sensitize people to overreact to an ... people who dont have a stress-related disorder, says new ... have long lasting effects on the brain and behavior ... But these subtle changes could increase susceptibility to mental ...
... the growing epidemic of diabetes in the US is out. ... . ,According to a drug trend report released ... cholesterol medications in total prescription drug spending growth in 2006. ... obesity a leading cause of diabetes are expected ...
... in the mouth like a popular breath-freshener could someday ... The innovative drug-delivery system was developed by Johns ... two-semester course, the seven-student team fabricated a thin film ... the child to swallow the vaccine. The dissolved medication ...
... become one of the first major universities in the country ... University officials intend to give the Fayetteville campus community ... the policy: the ban is scheduled to go into effect ... issue, said Mary Alice Serafini, assistant vice chancellor for student ...
Cached Medicine News:Health News:Trauma Exposure can Affect Brain Function Several Years After Event 2Health News:Spending on Diabetes Drugs Soars in US 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 2Health News:Students Devise Oral Quick-dissolve Strips for Rotavirus Vaccine 3Health News:University of Arkansas to Ban Tobacco from Its Campus 2Health News:University of Arkansas to Ban Tobacco from Its Campus 3
...
View Mex-2 is designed for out-patient surgery, hospital rounds and house calls....
It is a magnifying headlight perfect for all applications and procedures where clear magnification and a natural white light increase accuracy and productivity....
... is powerful, lightweight, easy ... soft, durable foam silicone ... covered by machine washable ... headband easily adjusts to ...
Medicine Products: